Effect Of Ubenimex On Antiangiogenic Effects In The Treatment Of LANSCLC

Objective:To investigate the effect of Ubenimex on the anti-angiogenic effect of local advanced non-small cell lung cancer(LANSCLC).Methods:Selected 48 patients with LANSCLC who met the inclusion criteria from May 2016 to May 2017 in the Second Affiliated Hospital of Hunan Normal University(clinical stage refers to the 2009 international TNM staging criteria:stageⅢAT1-2N2M0,T3N1-2M0,T4N0-iM0;ⅢBT4N2M0,T4N2-3M0),divided into 2 groups,24 cases in each group,detailed records of the gender,age,clinical stage,classification,KPS scores,etc Group:3-Dimensional conformal radiation therapy(3D-CRT),total dose set at 60-68 Gy,2 Gy/time,5 times per week;experimental group(Ubenimex plus3D-CRT),3D-CRT was administeredin the same manner as the control group + Ubenimex(10 mg orally 3/day)for 10 consecutive weeks from the first day.All 48 patients received peripheral venous blood(3mL)in an early morning fasting,and peripheral blood was collected at 0,6 and 10 weeks respectively.Enzyme-linked immunosorbent assay(ELISA)was used to measure serum vascular endothelial growth factor(VEGF).Results:1.Before treatment,the levels of VEGF in the control group and the experimental group were compared,After statistical treatment,there was no significant difference between the two groups.At the 6th week after treatment,the VEGF levels in the control group and the experimental group were compared and the statistical analysis was performed.There was no statistically significant difference between the two groups.At the 10th week after treatment,the levels of VEGF in the control group and the experimental group were significantly lower than those in the control group.Statistically,the difference was statistically significant.2.The effective rate of curative effect in the experimental group was higher than that in the control group.After statistical analysis,there was no significant difference between the two groups.3.(1)The incidence of 0-1 grade acute radiation lung injury was 37.5%and 12.5%in the control and experimental groups,respectively.The incidence of 0-1 in the experimental group was lower than that in the control group.The difference was statistically significant;(2)The incidence of grade 2 acute lung injury was 29.2%and 4.2%.The incidence of grade 2 in the experimental group was lower than that in the control group.Statistically,there was a statistically significant difference between the two groups.(3)The incidence of grade 3-4 acute radiation lung injury was 29.2%and 4.2%.The incidence of grade 3-4 in the experimental group was significantly lower than that in the control group.Statistically,the difference was statistically significant.(4)None of the 48 patients with LANSCLC treated with 3D-CRT,Ubenimex and 3D-CRT had grade v acute radiation-induced lung injury.4.The improvement of quality of life in the experimental group was higher than that in the control group.Statistically,there was a statistically significant difference between the two groups.The quality of life in the experimental group was lower than that in the control group.Statistically,the difference was statistically significant.Conclusion:Ubenimex reduces the serum level of VEGF in locally advanced non-small cell lung cancer,inhibits the function of vascular endothelial growth factor,and leads to inhibition of tumor angiogenesis.It may be a potential therapeutic drug for adjuvant treatment of LANSCLC.